# China NMPA Drug Inspection - Pfizer Pharmaceuticals Co., Ltd. - Azithromycin dry suspension

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/pfizer-pharmaceuticals-co-ltd/ed152038-f1e5-461e-8909-48ab05988aa2/
Source feed: China

> China NMPA drug inspection for Pfizer Pharmaceuticals Co., Ltd. published July 28, 2022. Drug: Azithromycin dry suspension. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Information Bulletin on Drug Quality Sampling Inspection in Qinghai Province (Issue 1, 2022)
- Company Name: Pfizer Pharmaceuticals Co., Ltd.
- Publication Date: 2022-07-28
- Drug Name: Azithromycin dry suspension
- Inspection Finding: qualified

Company: https://www.globalkeysolutions.net/companies/pfizer-pharmaceuticals-co-ltd/8b1407a5-b939-468d-a383-a7c7069b2207/